Ballicules.com

Methenamine hippurate

HIPREX

Methenamine hippurate ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Methenamine hippurate ballicule

What it isConverted to formaldehyde in acidic urine; recurrent urinary tract infection prophylaxis.

Why this oneIts formaldehyde mechanism largely avoids conventional antibiotic resistance and microbiome pressure.

What limits itUrine must remain below pH 6, and it cannot treat active infection; avoid sulfonamides and urine-alkalinizing drugs.

Methenamine hippurate molecular structure (skeletal formula)
Molecular structure: Methenamine hippurate

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Recurrent UTI — prophylaxis/suppressionAdults and children >12 yr1 g (1 tablet) BID (morning and night)1 g BID1 g BID
Recurrent UTI — prophylaxis/suppressionChildren 6–12 yr0.5–1 g (½–1 tablet) BID (morning and night)0.5–1 g BID1 g BID

Renal Contraindicated in renal insufficiency.

Hepatic Contraindicated in severe hepatic insufficiency.

Instructions

Available strengths

Contraindications

Cautions

Adverse reactions

Pregnancy Undefined

Lactation Undefined

Cost

Methenamine hippurate (HIPREX)
What pharmacies pay · NADAC 9/30/26
Strength#/mogeneric $/moCostPlus
1000 mgtab60 BID$18.76offered

Generic entry2003

NO BOXED WARNINGS

Principal riskIt needs urine pH below 6; prophylaxis only

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryUnknown / historical label unavailable

Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.

Open Methenamine hippurate in the interactive console ↗